Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, et al. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1. Clin Cancer Res 2020;26:2284-2289.
PMID: 32001481